



Healthcare
Improvement
Scotland

SMC
Advice on new
medicines

www.scottishmedicines.org.uk

Product update

SMC2511

levofloxacin 5mg/mL plus dexamethasone 1mg/mL eye drops solution (Duressa[®])

Santen UK Limited

07 October 2022

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

levofloxacin plus dexamethasone (Duressa[®]) is accepted for use within NHSScotland.

Indication under review: for prevention and treatment of inflammation, and prevention of infection associated with cataract surgery in adults. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

There is no significant additional cost associated with the combination product compared with the individual components and it allows patients to administer fewer drops.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 10 June 2022.

**Chairman
Scottish Medicines Consortium**

Published 07 November 2022